Tags

Type your tag names separated by a space and hit enter

Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab.
Indian J Ophthalmol. 2015 Jan; 63(1):25-9.IJ

Abstract

AIMS

To evaluate the 1-month efficacy of intravitreal triamcinolone acetonide (TA) in treating macular edema secondary to retinal vein occlusion (RVO) that was refractory to intravitreal bevacizumab.

MATERIALS AND METHODS

This retrospective, observational study included 23 eyes from 23 patients with macular edema secondary to RVO. Macular edema that did not respond to two or more consecutive intravitreal bevacizumab injections was treated with intravitreal TA. Central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were compared before and one month after TA injection.

RESULTS

Fifteen eyes were diagnosed with central RVO, and eight eyes were diagnosed with branch RVO. All patients were previously treated with 2.4 ± 0.6 intravitreal bevacizumab injections. The TA injection was performed, on average, 5.8 ± 1.4 weeks after the last bevacizumab injection. The CFT before TA injection was 516.6 ± 112.4 μm and significantly decreased to 402.3 ± 159.7 μm after TA therapy (P < 0.001). The logarithm of the minimal angle of resolution BCVA was 0.72 ± 0.34 before TA therapy and was not significantly improved by the treatment (0.67 ± 0.35, P = 0.119), despite a decrease in CFT. However, seven eyes (30.4%) had a BCVA gain of one or more lines.

CONCLUSIONS

Intravitreal TA therapy was beneficial in some patients with macular edema secondary to RVO that was refractory to intravitreal bevacizumab therapy. This study suggests that intravitreal TA should be considered as a treatment option for refractory macular edema.

Authors+Show Affiliations

No affiliation info availableDepartment of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, South Korea.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25686058

Citation

Yoo, Seul Gi, et al. "Short-term Efficacy of Intravitreal Triamcinolone Acetonide for Macular Edema Secondary to Retinal Vein Occlusion That Is Refractory to Intravitreal Bevacizumab." Indian Journal of Ophthalmology, vol. 63, no. 1, 2015, pp. 25-9.
Yoo SG, Kim JH, Lee TG, et al. Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab. Indian J Ophthalmol. 2015;63(1):25-9.
Yoo, S. G., Kim, J. H., Lee, T. G., Kim, C. G., & Kim, J. W. (2015). Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab. Indian Journal of Ophthalmology, 63(1), 25-9. https://doi.org/10.4103/0301-4738.151460
Yoo SG, et al. Short-term Efficacy of Intravitreal Triamcinolone Acetonide for Macular Edema Secondary to Retinal Vein Occlusion That Is Refractory to Intravitreal Bevacizumab. Indian J Ophthalmol. 2015;63(1):25-9. PubMed PMID: 25686058.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab. AU - Yoo,Seul Gi, AU - Kim,Jae Hui, AU - Lee,Tae Gon, AU - Kim,Chul Gu, AU - Kim,Jong Woo, PY - 2015/2/17/entrez PY - 2015/2/17/pubmed PY - 2016/11/9/medline SP - 25 EP - 9 JF - Indian journal of ophthalmology JO - Indian J Ophthalmol VL - 63 IS - 1 N2 - AIMS: To evaluate the 1-month efficacy of intravitreal triamcinolone acetonide (TA) in treating macular edema secondary to retinal vein occlusion (RVO) that was refractory to intravitreal bevacizumab. MATERIALS AND METHODS: This retrospective, observational study included 23 eyes from 23 patients with macular edema secondary to RVO. Macular edema that did not respond to two or more consecutive intravitreal bevacizumab injections was treated with intravitreal TA. Central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were compared before and one month after TA injection. RESULTS: Fifteen eyes were diagnosed with central RVO, and eight eyes were diagnosed with branch RVO. All patients were previously treated with 2.4 ± 0.6 intravitreal bevacizumab injections. The TA injection was performed, on average, 5.8 ± 1.4 weeks after the last bevacizumab injection. The CFT before TA injection was 516.6 ± 112.4 μm and significantly decreased to 402.3 ± 159.7 μm after TA therapy (P < 0.001). The logarithm of the minimal angle of resolution BCVA was 0.72 ± 0.34 before TA therapy and was not significantly improved by the treatment (0.67 ± 0.35, P = 0.119), despite a decrease in CFT. However, seven eyes (30.4%) had a BCVA gain of one or more lines. CONCLUSIONS: Intravitreal TA therapy was beneficial in some patients with macular edema secondary to RVO that was refractory to intravitreal bevacizumab therapy. This study suggests that intravitreal TA should be considered as a treatment option for refractory macular edema. SN - 1998-3689 UR - https://www.unboundmedicine.com/medline/citation/25686058/Short_term_efficacy_of_intravitreal_triamcinolone_acetonide_for_macular_edema_secondary_to_retinal_vein_occlusion_that_is_refractory_to_intravitreal_bevacizumab_ L2 - http://www.ijo.in/article.asp?issn=0301-4738;year=2015;volume=63;issue=1;spage=25;epage=29;aulast=Yoo DB - PRIME DP - Unbound Medicine ER -